Posted by Michael Wonder on 05 Jul 2016
Accelerated drug approval and health inequality
5 July 2016 - This Viewpoint argues that the acceleration of the drug approval process could unequally distribute the costs and burdens of testing to vulnerable patient populations.
In the United States, there is considerable political momentum for accelerating access to novel medications. Faster access is often portrayed as increasing fairness by providing treatment options to patients who currently lack them. There has been scant attention, however, to the broader effects such proposals would have on equity within health care and research.
